Arix Bioscience (LSE:ARIX)
Historical Stock Chart
2 Months : From Aug 2019 to Oct 2019
By Colin Kellaher
Clinical-stage biopharmaceutical company Imara Inc. Friday said it has confidentially filed a draft registration with the Securities and Exchange Commission for a proposed initial public offering.
The Boston company said the number of shares to be offered and the expected price range haven't yet been determined.
Imara is working to develop treatments for a group of rare, inherited genetic disorders of hemoglobin known as hemoglobinopathies. The company's initial product candidate, IMR-687, is in development for sickle cell disease and beta-thalassemia.
Imara in March raised $63 million in a Series B funding round led by Arix Bioscience PLC (ARIX.LN) and OrbiMed Advisors, with participation from RA Capital, Rock Springs Capital, Alexandria Venture Investments, Bay City Capital, Lundbeckfonden Ventures, New Enterprise Associates and Pfizer Ventures.
The filing Imara submitted to the SEC isn't yet visible to the public because the company has taken advantage of the commonly used confidential-filing provision introduced in 2012 as part of the Jumpstart Our Business Startups Act.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
September 13, 2019 08:11 ET (12:11 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.